AbbVie(ABBV) - 2025 Q4 - Annual Results

Earnings Guidance - For Q4 2025, AbbVie expects GAAP and adjusted non-GAAP earnings to include a pre-tax expense of $1.3 billion related to acquired IPR&D and milestones, negatively impacting earnings per share by $0.71[5] - The full-year adjusted diluted earnings per share guidance for 2025 is projected to be between $9.90 and $9.94, including the impact of the fourth quarter expenses[6] - The fourth quarter adjusted diluted earnings per share guidance is estimated to be between $2.61 and $2.65, factoring in the acquired IPR&D and milestones expense[6] Risk Factors - AbbVie does not forecast future acquired IPR&D and milestones expenses due to the uncertainty of timing and occurrence of related transactions[6] - The report includes forward-looking statements that are subject to various risks and uncertainties, including competition and regulatory changes[9] - AbbVie has filed its 2024 Annual Report on Form 10-K, which outlines additional risk factors that may affect its operations[9]